Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome

Abstract

The diagnosis and treatment of uterine LMS is challenging. Novel biomarkers offer hope for future therapies.

Distribution and survival of primary sarcoma in Korea: A single center analysis of 2017 cases

“…Leiomyosarcoma demonstrated 65.2% in 5-year OS in present study, which is similar with other reports (64.2%-65.7%) [20,21]. In subgroup analysis between uterus group (72.2%) with non-uterus group (62.4%) in leiomyosarcoma, demonstrated favor survivorship in uterus group than non-uterus group without statistical significance in present study.…”

Insulin‐like growth factor II messenger RNA‐binding protein‐3 is an independent prognostic factor in uterine leiomyosarcoma

“…Clinicopathological features were roughly concordant with those found in previous studies. 1,3,4,[6][7][8][9][10]30…”

Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma: 10‐year experience of a single institute

“…Uterine smooth muscle tumors of uncertain malignant potential share some characteristic features of ULMS, but do not fulfill all the criteria. Most ULMS lesions are hypercellular, with spindle‐shaped cells showing infiltrative borders and vascular invasion . Variants also exist, including epithelioid ULMS, which is characterized by round or polygonal cells with abundant eosinophilic or clear cytoplasm, and myxoid ULMS, which appears gelatinous, often lacks significant cytological atypia, and has a low mitotic index …”

“…Most ULMS lesions are hypercellular, with spindle-shaped cells showing infiltrative borders and vascular invasion. 6 Variants also exist, including epithelioid ULMS, which is characterized by round or polygonal cells with abundant eosinophilic or clear cytoplasm, and myxoid ULMS, which appears gelatinous, often lacks significant cytological atypia, and has a low mitotic index. 7 The primary treatment for ULMS is surgery, with the goal of complete resection.…”